FDA Approves First Muscle-Targeted Treatment ISEMBYLD for Spinal Muscular Atrophy

The U.S. Food and Drug Administration has approved the first muscle-targeted treatment for spinal muscular atrophy (SMA), but its use relies on a strict biological prerequisite: patients must already be receiving a foundational genetic therapy. The new drug, Isembyld (apitegromab-mstn), does not replace existing treatments that target the survival motor neuron 2 (SMN2) gene. Instead, it requires them to be in place, building upon that neurological stabilization to directly address the secondary symptom of severe muscle loss. Because a large majority of the SMA community is currently prescribed an SMN2-targeted therapy, this binding constraint is already met for thousands of patients, clearing the way for a dual-mechanism approach to the disease.[1][3]

SMA is a rare genetic disorder that damages motor neurons, leading to progressive muscle weakness that impairs movement, breathing, and swallowing. Over the past decade, the standard of care has been revolutionized by therapies like Biogen's Spinraza, Novartis's Zolgensma, and Roche's Evrysdi. These foundational treatments focus entirely on the neurological root of the condition, preserving motor neuron survival by boosting the deficient SMN protein. While highly effective at halting rapid decline, they do not directly rebuild the muscle tissue that has already atrophied.[2][4]

Isembyld, developed by Massachusetts-based Scholar Rock, introduces a complementary mechanism. Chemically known as apitegromab, the drug selectively blocks the activation of myostatin, a protein that naturally limits muscle growth in the human body. By inhibiting myostatin, Isembyld aims to increase muscle mass and strength in patients whose motor neurons have already been stabilized by their background therapy. The drug is administered once every four weeks as an intravenous infusion by a healthcare professional.[1][5]

The FDA's approval rests primarily on data from the 52-week Phase 3 SAPPHIRE trial, which enrolled 188 nonambulatory patients aged 2 to 21. In the primary efficacy analysis focusing on children aged 2 to 12, those receiving a 10 milligram per kilogram dose of Isembyld demonstrated a statistically significant 2.2-point improvement on the Hammersmith Functional Motor Scale Expanded (HFMSE) compared to a placebo group at the one-year mark.[3][5]

The clinical difference was most pronounced in the responder data. According to the trial results, 34.2% of patients receiving the 10 mg/kg dose achieved at least a 3-point improvement on the HFMSE, a threshold considered clinically meaningful for daily independence. In contrast, only 13.5% of patients receiving the placebo reached that mark. While the placebo group generally saw their motor function decline over the 52 weeks, the treated group stabilized or improved.[3]

"The significance really lies in the fact that apitegromab addresses a different pathway from what all the SMA restoration therapies have done," said Brian Lin, research director at the Muscular Dystrophy Association. "This is a therapy that can serve as a complementary therapy or a combination therapy and add on a certain level of efficacy beyond just what the SMN [therapies do]."[2][3]

The FDA cleared Isembyld for adults and children two years of age and older. Scholar Rock indicated that the drug will be available to ship in the coming days, though the company has not yet disclosed pricing details for the monthly infusion regimen. The manufacturer was also awarded a Rare Pediatric Disease Priority Review Voucher by the FDA, which can be used to expedite the review of a future drug application.[1][4]

The authorization marks the first regulatory approval for Scholar Rock, positioning the company within a rapidly evolving neuromuscular market. Financial analysts project significant demand for a therapy that can layer on top of existing genetic treatments. BMO Capital Markets forecasts that Isembyld could reach $2.1 billion in adjusted worldwide peak sales by 2035, reflecting the broad applicability of the drug across the SMA population that is already managing the disease with SMN2-targeted therapies.[4][6]